Top of this page
Skip navigation, go straight to the content

Clinical Studies Clinical studies index

Clinical Studies Index

UCB is committed to sharing information on studies

and making study results publicly accessible


Scope of studies

This site provides information on both ongoing and completed studies sponsored by UCB for products commercially available and under development. It is searchable via the Compounds menu on top.

Information is available for the following:

  • Phase 2-4 interventional* clinical studies which began on or after 1 January 2004
  • Phase 2-4 interventional* clinical studies which began prior to 1 January 2004 and were considered pivotal to regulatory approval of core UCB medicines.
  • Other studies that were available on the initial version of UCB’s study internet page.

UCB discloses information regardless of the outcome of the study or where the study was conducted.

This list will be updated regularly.

* For a description of ‘interventional studies’ or to learn more about clinical studies in general, click here, and for additional definitions of terms related to clinical studies, click here.

employee working on the laboratory (zoom picture)
Veronique, UCB employee working on the laboratory


general laboratory picture

Lay summaries of study results

Briviact logo
Vimpat logo
keppra logo
image description
Microscope and laboratory things

Access to study data request

Qualified researchers may request access to anonymized patient-level data and supporting documents that have been redacted to protect personally identifiable information, from UCB-sponsored clinical studies via the Clinical Study Data Request (CSDR) website.

CSDR is a consortium of clinical study Sponsors/Funders and facilitates the responsible sharing of patient-level data from a range of clinical study Sponsors/Funders through a researcher-friendly platform.

In addition to the studies already listed on CSDR, UCB will consider ad hoc requests for additional Phase 2-4 UCB-sponsored interventional clinical studies that started on or after 01 January 2007 to be added to CSDR. Additional information is available at the Clinical Study Data Request website.


Study information

For each study information on the disease area studied, study type and recruitment status are provided. Results will also be added as they become available. There is also a link to the protocol information on and, if available, on the

Completed studies, which were conducted with a product approved in at least one country, have results presented in a tabular format via or as a brief summary, in accordance with international guidelines (ICH E3). Where available, a summary in lay terms and references to publications are included as well.

Further clinical studies and results are available on and


Additional information

For more information on UCB marketed products and UCB pipeline compounds, you may also navigate to the Products page or to the Pipeline page.

Should you have any questions, you can contact us at

general laboratory things


Clinical study results are intended to report the results of the study that were known at the time of the study's completion.
The results therefore do not provide a comprehensive and current review of the safety and efficacy of any compound based upon all information available.